Targeted delivery of irinotecan and SLP2 shRNA with GRP-conjugated magnetic graphene oxide for glioblastoma treatment-Reference-Cited by-同舟云学术

Targeted delivery of irinotecan and SLP2 shRNA with GRP-conjugated magnetic graphene oxide for glioblastoma treatment

Published:2022 Issue:12 Volume:10 Page:3201-3222
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Chuang Chi-Cheng¹²,Lan Yu-Hsiang²,Lu Yu-Jen¹²,Weng Yu-Lun³,Chen Jyh-Ping¹³⁴⁵⁶^ORCID

Affiliation:

1. Department of Neurosurgery, Chang Gung Memorial Hospital, Linkou, Kwei-San, Taoyuan 33305, Taiwan

2. College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan

3. Department of Chemical and Materials Engineering, Chang Gung University, Taoyuan 33305, Taiwan

4. Department of Plastic and Reconstructive Surgery and Craniofacial Research Center, Chang Gung Memorial Hospital, Linkou, Kwei-San, Taoyuan 33305, Taiwan

5. Research Center for Food and Cosmetic Safety, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 33302, Taiwan

6. Department of Materials Engineering, Ming Chi University of Technology, Tai-Shan, New Taipei City 24301, Taiwan

Abstract

Chitosan/urocanic acid modified mGO can anchor GPR, complex SLP2 shRNA and bind CPT-11 for dual targeted drug/gene delivery. Intravenous administration plus magnetic guidance provides excellent glioblastoma treatment in a murine brain tumor model.

Funder

Chang Gung Memorial Hospital

Ministry of Science and Technology, Taiwan

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2022/BM/D2BM00420H

Reference71 articles.

1. Improved survival time trends for glioblastoma using the SEER 17 population-based registries

2. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016